Feedback Share Discussion Threads

[21trader] 27/4/2015 07:54

Annoying just 4 days after the no reason for the rise they issue even more news
after the previous news.

Bad move by management on last weeks Rns.

[blueball] 27/4/2015 07:28

Do we have an early morning RNS..?

[lr2] 26/4/2015 22:05

You're welcome Norbert. Just trying to be helpful.

[norbert colon] 26/4/2015 21:46

Interesting information LR2 - thanks for posting.

[alicia1983] 26/4/2015 20:44

hxxp://www.europeanurology.com/article/S0302-2838%2814%2900633-2/pdf/the-cost-of-stone-surgery

[blueball] 26/4/2015 19:37

FDA approval will be a big turning point for the company and the tie up with IE2 suggests it wont be too long coming.

Novel technology with no current competitors...things are moving fast.

[lr2] 26/4/2015 19:00

The US web site is called Clinical Trials. The trial is sponsored by Bayer Pharmaceuticals. It seems to me that FDA approval must shortly be forthcoming for this trial to go ahead.

Quote that follows is from the Feedback Chairman in the Year End report from last October. The company and Imaging Endpoints are now doing precisely what their stated ambition was for the product.

"TexRAD continues to develop its product into a commercial version for the pharmaceutical trials market while maintaining sales of its research version to the leading oncology research centres in hospitals around the world. The board is pleased to announce that the Company is about to seek regulatory approval for TexRAD to be used in pharmaceutical trials and are hopeful that FDA approval can be achieved within the coming financial year.

Ahead of the launch of the pharmaceutical trials version of the TexRAD software the Group has reconfirmed its arrangements with Imaging Endpoints II, LLC ("IE2") in the USA. As set out in the Company's admission document, TexRAD entered into a software licence agreement and strategic partnership with IE2 in which TexRAD granted IE2 the exclusive licence to use TexRAD Research Software in the state of Arizona in the USA, and to use TexRAD Clinical Trial Software worldwide with an expected termination date of 12 September 2014. This agreement has now been re-signed on substantially the same terms and will run for two years from the validation date of the TexRAD Clinical Trial Software, i.e. the date at which it has achieved compliance with 21 CFR part 11 of the Code of Federal Regulations. IE2 will therefore remain our exclusive partner worldwide for imaging core lab purposes."

[blueball] 26/4/2015 15:44

Great find FDA approval within the next 2 months would be a big breakthrough for all connections.

[lr2] 26/4/2015 12:31

Bayer Healthcare Pharmaceuticals, Inc. / Bayer Schering Pharma are sponsoring the following "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX".



This US based Colorectal Cancer study was posted up on the US Government National Institutes of Health site last Thursday (the same day as the share price movement RNS). It is still in the recruiting participants phase.

What makes this particular study interesting, I reckon, is the following paragraph in the Detailed Description section.

"In addition, evaluating the Texture (spatial variations in pixel intensity) in computed tomography (CT) scans might help predict the risk of recurrence. Therefore, CT disks will be sent to Imaging Endpoints Core Lab, Scottsdale, AZ, where the TexRAD platform (a software algorithm) will be used for analysis."

This could be a significant breakthrough for FDA approval.

[21trader] 24/4/2015 12:25

Company killed it. Took a tiny profit could see nobody was buying it after that Rns but I will be back soon.

[daijavu] 24/4/2015 10:16

A couple of weeks

[blueball] 24/4/2015 09:49

How long have you been posting..?

[daijavu] 24/4/2015 09:47

I can't trade online in FDBK shares, there is no record of any trades by anyone in FDBK shares since yesterday and no one is posting anything about FDBK on here or lse.

Has the company gone into administration but no one has told us?

[reestie3] 23/4/2015 16:28

Good to see Stig filtered. His multiple posts are always totally meaningless and deramping. His comments are never supportive of investors.

[the stigologist] 23/4/2015 13:44

it was an overdone move and the company probably a bit embarrassed about the rise which has come about more due to the illiquidity than any real fundamental analysis

they dont have a cure for cancer it is just a software tool used for analysis by a limited community of specialist users so it doesnt have the scalability of a normal software business or the wonder drug potential of a biotech

the balance sheet is weak and i suspect placing imminent which would be further reason for company or nomad to calm the rampers who will only start crying if there is a placing at big discount

[21trader] 23/4/2015 13:11

I can understand the AVO Rns I thought and said on twitter when Avo valuation
hit 150-160 million it was crazy for now and getting out of control and the price has dropped 40-50% since then.

But is a increase of about 1.75 mil in valuation crazy for the news issued. Where
cancer is concerned I think not but the company thinks otherwise.

[tomboyb] 23/4/2015 13:03

Or if the MMs think they cannot have an orderly market and are not in control -

The dirs hold quite a few - They have said no reason so unless the buyers keep buying this will probably settle here or a bit lower -

[lr2] 23/4/2015 13:02

Yep, just a couple more deals and they should be making profits.

[blueball] 23/4/2015 12:50

Nothing to worry about share price off 5%.

I like the bit when they say they are in discussions with potential customers nice touch.

[lr2] 23/4/2015 12:43

Almost certainly it wasn't the company's idea to release that. These 'Price Movement' items are normally at the behest of the Nomad. In this case, Sanlam Securities. Probably just another way of shaking the tree to get a few shares released so they can grab them for their clients. Hasn't worked so far, I see.

[113mike] 23/4/2015 12:40

Yea..stinks doesn't it?

[21trader] 23/4/2015 12:29

Who's going to buy their shares if they issue 2 bits of good news and then say no reason for the rise. It's only gone from 1.5p offer to 2.5p offer the whole idea
of good news is to increase the share price. Now if it was 4p I could understand
it but the price was not moving at the time of Rns and there was little action in the previous 2 hours.